Abstract Library

#2087 Prospective, Multi-Center, Open Label, Phase Study II of APOC, a New Controlled Release 15mg Octreotide Acetate, for the Treatment of Advanced NETs

Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy of advanced NETs. The efficacy controlling hormone release and tumor growth together with the favorable toxicity profile have positioned SSAs as upfront therapy. Despite of second-line therapies including targeted agents, chemotherapy and radiolabeled peptides have demonstrated activity controlling tumor growth, the less favorable toxicity profiles become a usual discussion with patients (pts) to preserve the quality of life (QoL). Additionally, from concordant flow of evidences clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products. APOC is a new controlled release ready-to-use convenient therapeutic, designed to cover specifically these clinical unmet needs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Capdevila J

Authors: Capdevila J, Hernando J, Casanovas O, Lachamp L, Cabello F,

Keywords: Somatostatin analogues, New release mechanism, High doses,

#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors

Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Daskalakis K

Authors: Daskalakis K, Norlén O, Karakatsanis A, Hellman P, Larsson R,

Keywords: Ex vivo activity, Cytotoxic drugs, Targeted agents, small intestinal neuroendocrine tumors,

#1667 A Qualitative Exploration into the Experience of Neuroendocrine Pancreatic Cancer Patients Receiving Molecular Targeted Therapies

Introduction: Despite extensive efficacy date and limited data examining drug related side effects, the patient experience and quality of life data is limited for this patient group

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Quaglia E

Authors: Quaglia E, Uzzell M, Woodcock J, Caplin M,

Keywords: Sunitinib, everolimus,

#1297 Efficacy and Safety of Targeted Agents for Treatment of Gastroenteropancreatic (GEP) Neuroendocrine Tumor (NET): Single Center Experience

Introduction: As clinical features of NET are heterogeneous, the evaluation of real-world outcomes with everolimus and sunitinib are necessary.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Yoo C

Authors: Yoo C, Cho H, Kim K, Chang H, Kim T,

Keywords: everolimus, sunitinib, gastroenteropancreatic NET,

#1059 Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era

Introduction: We have conducted molecular profiling through high-throughput molecular test as part of clinical practice for patients with advanced gastrointestinal (GI) cancer, or rare cancer including gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Park Y

Authors: Kim S, Yoo K, Jung K, Lee S, Lee J,

Keywords: molecular profiling, GEP-NET,